	US 12,403,132 B2
	Methods of treating bone marrow failure syndromes and compositions for use in the same
Kathleen Miho Sakamoto, Stanford, CA (US); and Mark Wilkes, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Appl. No. 17/924,601
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
PCT Filed Jun. 24, 2021, PCT No. PCT/US2021/038987 § 371(c)(1), (2) Date Nov. 10, 2022, PCT Pub. No. WO2022/005879, PCT Pub. Date Jan. 6, 2022.
Claims priority of provisional application 63/046,877, filed on Jul. 1, 2020.
Prior Publication US 2023/0172917 A1, Jun. 8, 2023
Int. Cl. A61K 31/4375 (2006.01); A61K 31/155 (2006.01); A61K 36/258 (2006.01); A61P 7/00 (2006.01)

CPC A61K 31/4375 (2013.01) [A61K 31/155 (2013.01); A61K 36/258 (2013.01); A61P 7/00 (2018.01)]

12 Claims

1. A method of treating a subject diagnosed as having a bone marrow failure syndrome, the method comprising:

administering to the subject an effective amount of a nemo-like kinase (NLK) inhibitor to treat the subject for the bone marrow failure syndrome.